Clinical Trials Browser

Lymphoma, T-Cell × duvelisib × 30 days × Clear all

NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2 Suspended

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT07293403 2026-06-02

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Phase 2 Recruiting

Lymphoma, T-Cell